| This week's sponsor is Premier Research. | | | Atopic Dermatitis: Where Do We Go From Here?
Improved understanding of atopic dermatitis is revealing new insights and treatment options. Get current by downloading our white paper examining these exciting and emerging therapies. Premier Research. It's what we do. Best. |
Today's Rundown FierceBiotech’s top 10 stories of the year: Mergers, cuts and setbacks INC Research and inVentiv Health merge in another major CRO deal Shire will cut U.S. locations and move HQ in consolidation push [Sponsored] Addressing Placebo Response, Therapeutic Misconceptions and Expectations GlaxoSmithKline stops development of 30 pipeline prospects, mulls sale of rare disease unit as new CEO Walmsley makes her mark FierceBiotech's 2017 Fierce 15 The top 10 pharma R&D budgets in 2016 Roche splashes $1.7B in cash for Ignyta and entrectinib After impressing at ASCO, Legend gains Johnson & Johnson as new CAR-T partner Featured Story | | | Friday, December 22, 2017 We all love a top 10: It serves as a definitive "best of the best," and sometimes a look at the top of the chart can reflect the state of an industry. |
|
|
Top Stories Wednesday, May 10, 2017 Quintiles and IMS Health came together last year in a massive $19 billion megamerger, and now INC and inVentiv are looking to follow suit, combining into one new major company that will according to the pair make it the second largest biopharmaceutical outsourcing provider in the world. Wednesday, July 5, 2017 Shire has decided to concentrate its U.S. operations into two main sites in Massachusetts—Cambridge and Lexington—in a move that will probably lead to the closure of some sites. Monday, December 18, 2017 Randomized, placebo-controlled clinical trials are the most complex step in the development of new drugs. A contributor to trial failure is the increased rate of placebo response, which is now historically high. How can these trends be reversed? Wednesday, July 26, 2017 GlaxoSmithKline is scrapping more than 30 drug development programs. The major cull of pipeline prospects will see GSK focus 80% of its R&D budget on the top candidates in four therapeutic areas and potentially exit the rare disease space. Tuesday, September 26, 2017 The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the brightest teams, and we want to see the promise that they hold in their hands has a genuine chance of being the Next Big Thing. This year’s crop comprises some of the best-funded startups we’ve seen and speaks volumes about the rude health of early-stage biomedical research. Wednesday, April 26, 2017 Last year, biopharma won its share of new drug approvals as R&D spending came to fruition, but drugmakers also suffered a number of setbacks, cut research staff, rejigged their operations and refocused their pipelines. Friday, December 22, 2017 Swiss Big Pharma Roche has given Ignyta an early Christmas present in the form of a $1.7 billion buyout, worth $27 a share. Friday, December 22, 2017 Dark horse Nanjing Legend Biotech was one of the surprising stars of ASCO this summer with its CAR-T data, and now Johnson & Johnson is paying $350 million upfront to join forces with the company and look for a working “cure” for certain blood cancers. Resources Sponsored by: Seton Hall Don’t miss this educational program trusted by multi-national companies as part of their employee’s compliance training. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating in the Asia-Pacific region. Visit event page for session topics. Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA BIO CEO & Investor Conference February 12-13, 2018 | New York, New York Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | 